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2195-207.Submitted Jan 17, 2014; accepted Mar 14, 2014.DISCUSSIONDr Peter R. Nelson (Tampa, Fla). I would like to commend
Dr Stone and the group fromWest Virginia on an excellent presen-
tation and a well-written manuscript.
As a specialty, despite technical advances, we continue to be
plagued by the poor durability of lower extremity revasculariza-
tion, whether it is percutaneous intervention or vein bypass sur-
gery. There are at least 12 papers at the Southern Association
for Vascular Surgery meeting alone focused on outcomes in pe-
ripheral arterial disease, including talks ranging from emphasizing
patient-centric end points to the effect of race or gender on out-
comes, the role of polymorphisms in the p27kip1 gene and their
effect on cellular regulation and intimal hyperplasia, and even
how an individual’s personality type affects outcomes in
claudication.
Dr Stone and his colleagues have added new knowledge to
this effort by focusing on two common cardiovascular biomarkers,
high-sensitivity C-reactive protein (CRP) and brain natriuretic
peptide (BNP), and their potential to better predict outcomes
and complications after lower extremity intervention. In summary,
they have shown that
d Elevated preintervention levels of CRP may predict a higher
rate of adverse limb events, but the association was limited
only to patients undergoing infrainguinal intervention.
d Elevated levels of BNP were not associated with limb events.
d Elevated levels of both CRP and BNP were independently
associated with higher rates of major adverse cardiac events
(MACE).
d And, perhaps most dramatic, the combination of the two
markers was highly predictive of a 10-fold increase in MACE.I offer the following three questionsdone mechanical, one
strategic, and one philosophical:
1. First, several areas of potential bias exist. The 118 patients
during 6 years equals approximately 20/year. What percent-
age of the total number of patients receiving intervention
during that time frame does this represent, and what degree
of selection bias does this introduce? Also, there was a prepon-
derance of iliac disease and claudication in your cohort, but
the association of CRP to limb events was seen only in the
infrainguinal subset, or 40% of the overall group. How does
this affect the statistical power of this comparison, and would
the same results be seen if a higher prevalence of critical limb
ischemia were studied?
2. Next, you focused on preoperative biomarker values. Why not
follow serial postoperative levels, and what might they add?
With this in mind, did you try to model class prediction
both with and without the biochemical markers to see if
they added signiﬁcant predictive value over use of conven-
tional clinical variables (ie, ankle-brachial index, smoking, clo-
pidogrel, cholesterol/statins, Rutherford score, TransAtlantic
Inter-Society Consensus II grading, diabetes) alone?
3. Last, where do we go from here? As you know, we and
others have also been interested in this line of investigation
and have found CRP to be of limited value. Is it time to
look past CRP, at least for limb-, stent-, or bypass-related
events? Also, can we expect one biomarker to tell the whole
story, or do we need to start thinking about using combina-
tions of markers to create speciﬁc predictive proﬁles that may
have more clinical utility? Say, if we looked at about six
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value and then created a real-time, point-of-care assay,
should this be the Holy Grail?
I would again like to congratulate Dr Stone on an investigative
strategy that could eventually get us to the point of true “person-
alized medicine” and planning of a treatment strategy based, at
least in part, on preoperative biochemical signatures.
Thanks to the Program Committee for the opportunity to
discuss this important paper.
Dr Patrick A. Stone. I will start with the ﬁrst question on
overall practice and selection bias. The previous chairman of our
department, who was a progressive thinker, advised me to check
high-sensitivity CRP (hsCRP) and BNP levels of all patients preop-
eratively, and this has been a standard outpatient order for me for
more than 5 years. This being said, patients were more commonlyclassiﬁed with claudication compared with critical limb ischemia,
which is a more common inpatient consultation.
I have not checked these biochemical markers serially. One of
the things I am doing now is looking at the patients who return for
repeated interventions (ie, the infrainguinal bypass). When they
come back in for a secondary procedure for vein grafts, stenosis,
and the like, they are coming in for an elective procedure, so they
will have another baseline CRP value to provide more information,
including whether hsCRP predicts future vein graft restenosis.
I think as vascular surgeons we are going to be judged more in
the future on how cost-effective our practice has become. It would
be nice if we could check someone’s hsCRP level and determine
that there is a higher rate of failure with interventions in patients
with elevated hsCRP; then elective procedures should be reconsid-
ered until hsCRP can be improved.
